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Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most 
common cause of chronic liver disease worldwide. 
Currently, the routinely used modalities are unable to 
adequately determine the levels of steatosis and fibrosis 
(laboratory tests and ultrasonography) or cannot 
be applied as a screening procedure (liver biopsy). 
Among the non-invasive tests, transient elastography 
(FibroScan®, TE) with controlled attenuation parameter 
(CAP) has demonstrated good accuracy in quantifying 
the levels of liver steatosis and fibrosis in patients 
with NAFLD, the factors associated with the diagnosis 
and NAFLD progression. The method is fast, reliable 
and reproducible, with good intra- and interobserver 
levels of agreement, thus allowing for population-wide 
screening and disease follow-up. The initial inability 
of the procedure to accurately determine fibrosis and 
steatosis in obese patients has been addressed with 
the development of the obese-specific XL probe. TE 
with CAP is a viable alternative to ultrasonography, 
both as an initial assessment and during follow-up of 
patients with NAFLD. Its ability to exclude patients 
with advanced fibrosis may be used to identify low-risk 
NAFLD patients in whom liver biopsy is not needed, 
therefore reducing the risk of complications and the 
financial costs.
Key words: Non-alcoholic fatty liver disease; Transient 
elastography; Controlled attenuation parameter
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Core tip: Non-alcoholic fatty liver disease (NAFLD) 
patients are at risk of NAFLD-related cirrhosis and 
resistance (IR), the basic pathogenetic factor underlying 
NAFLD and MetS. The main problem in assessing MetS 
risk is that it is not a disease but a clinical syndrome. 
MetS is manifested by the clustering of acquired 
metabolic factors that primarily increase the likelihood 
of cardiovascular events (myocardial infarction, stroke, 
and peripheral arterial disease). Thus, it has been 
suggested that NAFLD should be included as a fifth risk 
factor in the definition of MetS (the other four factors 
include obesity, dyslipidemia, arterial hypertension and 
glucose intolerance/diabetes mellitus); however, others 
consider NAFLD not as a hepatic manifestation of MetS 
but a separate condition only associated with MetS[3,4]. 
Whether the former or latter is true, NAFLD is strongly 
associated with all components of MetS. The prevalence 
of NAFLD in the general population is 20%-30%, 
whereas the prevalence rates are approximately 50%, 
50%-90%, 30%-50%, and 80%-90% in patients 
with hypertension, hyperlipidemia, T2DM, and obesity, 
respectively. Compared with MetS, one-third of patients 
with NAFLD have MetS, and 90% of NAFLD patients 
have at least one positive MetS criterion[5-7].
However, cross-sectional studies cannot define 
the time relationship between NAFLD and MetS 
components. The general belief that MetS precedes 
NAFLD has been questioned after a longitudinal study 
demonstrated an increased risk for the development 
of MetS in NAFLD patients (HR = 1.70, 95%CI: 
1.55-1.87)[8]. The similar, yet opposing effect of MetS 
increasing the risk for NAFLD development has also 
been confirmed, with a slightly increased hazard 
ratio (1.94, 95%CI: 1.78-2.13) compared with that 
reported in the previous study[9]. This bidirectionality 
is not limited to the occurrence of NAFLD and MetS; 
it also affects MetS components and disease severity. 
The presence of NAFLD increases the risk of developing 
arterial hypertension (HR = 1.07, 95%CI: 1.00-1.15 
for mild steatosis; HR = 1.14, 95%CI: 1.00-1.30 for 
severe steatosis) and type 2 diabetes mellitus (two-
fold risk increase)[10,11]. However, the presence of MetS 
increases the risk of developing NAFLD, depending 
on the number of MetS components present, with 
the combination of dyslipidemia and central obesity 
carrying a 3.01 hazard ratio (95%CI: 2.68-3.37) of 
NAFLD development. NAFLD severity is also affected 
by the presence of MetS, which increases the risk of 
inflammation - NASH (OR = 3.2, 95%CI: 1.2-8.9) and 
severe fibrosis (OR = 3.5, 95%CI: 1.1-11.2)[12]. Of 
the individual components, the strongest correlation 
appears to occur with abdominal obesity. A 1% 
increase in visceral fat carries an OR of 2.4 (95%CI: 
1.3-4.2) for increasing liver inflammation and an OR 
of 3.5 (95%CI: 1.7-7.1) for increasing fibrosis. The 
predictive value regarding advanced steatohepatitis 
and fibrosis remains after correcting for IR and hepatic 
steatosis, with an OR of 2.1 (95%CI: 1.1-4.2) for 
advanced steatohepatitis and an OR of 2.9 (95%CI: 
1.1-4.2) for fibrosis[13]. From a clinical viewpoint, the 
presence of NAFLD increases the risk of cardiovascular 
Mikolasevic I et al . TE with CAP in NAFLD
7237 August 28, 2016|Volume 22|Issue 32|WJG|www.wjgnet.com
hepatocellular carcinoma, particularly in the setting 
of liver fibrosis with concurrent metabolic syndrome. 
Transient elastography (TE) with controlled attenuation 
parameter (CAP) is a fast, reliable, repeatable non-
invasive method for the assessment of liver steatosis 
and fibrosis. TE with CAP may be used to diagnose 
and monitor patients with NAFLD. TE with CAP is a 
favorable means of excluding advanced fibrosis.
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INTRODUCTION
An increasingly common cause of chronic liver disease 
in adults and children is nonalcoholic fatty liver disease 
(NAFLD). In adults, the prevalence of NAFLD ranges 
from 17% to 33%[1], whereas in children, it ranges from 
2.6% to 9.6%, and from 22.5% to 44% in children 
with obesity[2]. Because of the ongoing epidemics 
of metabolic syndrome (MetS) and its individual 
components, the incidence of NAFLD is increasing in 
both adults and children. The individual components 
of MetS include diabetes mellitus type 2 (T2DM), 
obesity, arterial hypertension and dyslipidemia. The 
presentation of NAFLD may vary from simple steatosis 
to nonalcoholic steatohepatitis (NASH), liver cirrhosis 
and hepatocellular carcinoma (HCC)[1-4]. It is expected 
that NASH related cirrhosis and NASH related HCC may 
soon become the most frequent indications for liver 
transplantation [1]. Interestingly, in patients with NAFLD, 
liver-related mortality is the third cause of death and 
malignancy, whereas cardiovascular diseases are the 
main cause[1]; thus, cumulative evidence indicates 
that NAFLD is correlated with many extrahepatic 
diseases[1-3]. Many authors have suggested that NAFLD 
is not only a marker of MetS but also a risk factor for 
cardiovascular diseases (CVD), chronic kidney disease 
(CKD) and T2DM. Moreover, it is a risk factor for 
malignancy (colorectal carcinoma) and other conditions 
(sleep apnea, osteoporosis, psoriasis, and polycystic 
ovary syndrome)[1,3]. The clinical implication of these 
findings is that NAFLD patients may benefit from more 
intensive monitoring and early therapeutic interventions 
to lower the risk of cardiovascular and kidney diseases, 
as well as the risk for malignancies, HCC and colorectal 
carcinoma[3].
NAFLD AND METS
The association of NAFLD with MetS has been described 
with respect to the relation of both conditions with insulin 
event-associated deaths by approximately two-fold, 
independently of other cardiovascular risk factors[14,15].
PATHOGENESIS OF NAFLD
The pathogenesis of NAFLD remains an unsolved 
problem with a plethora of implications and potential 
solutions for clinical practice. Many people are 
affected by NAFLD; however, most (approximately 
60%-70%) remain asymptomatic, with simple liver 
steatosis. The main challenge faced by researchers 
is the identification of patients in whom the disease 
will progress and why. Elucidating the details of 
pathogenesis will provide the answer to this question, 
thereby allowing researchers to focus on the 
30%-40% of NAFLD patients who require intensive 
observation, follow-up and prevention (treatment) to 
halt the development of cirrhosis and HCC[16,17].
The central role in the development of NAFLD 
is reserved for IR. IR disrupts lipid metabolism by 
increasing peripheral fatty acid release. The increased 
free fatty acid levels combined with hyperinsulinemia 
result in the development of hepatic IR and increased 
hepatic triglyceride synthesis. Hepatic triglycerides 
accumulate as fat droplets in hepatocytes, thus 
resulting in what is referred to as a fatty liver[18,19]. 
Whether IR may represent a consequence of NAFLD 
appears to have been disproved by the discovery of 
specific genetic mutations (e.g., PNPLA gene), which 
result in the development of NAFLD without peripheral 
IR[20]. This simplistic view is mirrored by the lack of 
an effect of IR-reducing medications on NAFLD and 
the current lack of an effective, established anti-
NAFLD treatment other than lifestyle modifications and 
increased physical activity. IR affects NAFLD; however, 
the interplay of multiple factors appears to affect the 
character of the disease[3,21].
Another important factor underlying NAFLD is 
oxidative stress. Multiple studies have demonstrated 
a close relationship among mitochondrial dysfunction, 
the overproduction of reactive oxygen species (ROS) 
and NAFLD, namely, NASH[22,23]. Imperfect fatty acid 
degradation results in increased free radical production, 
which is manifested by the production of various lipid 
peroxides. If sufficient mitochondria are affected, the 
resulting leak of mitochondrial components may induce 
hepatocyte apoptosis[24,25].
Extracellular signals, such as proinflammatory 
cytokines, also appear to affect the development 
of NAFLD. Studies have demonstrated an effect of 
free hepatocyte lipids on the induction of various, 
predominately proinflammatory, intracellular signaling 
pathways (NF-κB, c-Jun, and diacylglycerol), which 
in turn worsen IR and contribute to the hepatic pro-
duction of various proinflammatory cytokines (e.g., 
interleukin-6 and tumor necrosis factor α)[26].
In previous years, studies have implicated gut 
microbiota dysbiosis as a potential building block in 
NAFLD pathogenesis. The effect does not appear to 
be directly mediated by bacteria; instead, it may be 
mediated by various bacterial products that enter 
the portal blood stream. Moreover, the mechanisms 
include the effects of bacteria-produced short-chain 
fatty acids on the energy balance and intestinal barrier 
permeability of the host, the effect of bacteria on 
intestinal motility and the effect of various absorbed 
toxins (lipopolysaccharides) on the liver[27].
The main challenge with understanding NAFLD 
pathogenesis is correctly positioning the small pieces 
(risk factors) in their respective places to “see the 
big picture”. Currently, there are three main theories 
regarding how the “pieces” should be positioned: the 
“two-hit”, “multi-hit” and “distinct-hit” theories[28].
The two-hit theory was initially suggested in the 
late 1990s. It is based on the finding that only a 
portion of patients with a fatty liver develop advanced 
forms of NAFLD, indicating that the “first hit”, IR-
induced liver steatosis, is like a barrel of gasoline that 
requires a “second hit”, ignition (e.g., mitochondrial 
dysfunction, cytokines, or bacterial endotoxins), for 
activation[29].
The theory is highly contested because of findings 
that some patients develop hepatic inflammation 
without pre-existing IR, and in most patients, more 
than two factors are typically present. Thus, the 
second “multiple parallel-hits” theory was created. It is 
based on the premise that the “first hit” is not a single 
factor, but a sum of multiple distinct factors that wear 
down liver defenses. Again, the basic mechanism is IR 
and its associated metabolic disturbances. The result, a 
fatty liver, is prone to multiple “hits”, which wear down 
liver defenses and eventually lead to inflammation 
(NASH) and fibrosis[30].
In recent years, a third “distinct-hit” theory has 
been proposed. It is based on the presumption that 
NAFLD and NASH are two separate diseases, which 
are associated with IR but unrelated to each other. 
This theory is based on epidemiological data indicating 
that patients with NASH have a 10%-20% chance of 
disease progression to cirrhosis during a 5-10-year 
period, whereas individuals with NAFLD typically 
manifest a stable disease, with a low risk of disease 
progression. Other data include the previously de-
scribed genetic NASH predisposition, in which liver 
inflammation occurs without peripheral IR[31,32].
TRANSIENT ELASTOGRAPHY 
(FIBROSCAN®) WITH CONTROLLED 
ATTENUATION PARAMETER
In clinical practice, the initial diagnosis of NAFLD 
is typically established through laboratory findings 
(increased levels of aminotransferases and gamma-
glutamil transferases) and radiological imaging 
techniques in the absence of other recognized causes 
of fatty liver (e.g., alcohol, virus, drugs, or autoim-
munity). Because of space limitations, this review will 
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on Hook’s law, which states that the velocity of 
shear waves that travel through an elastic object is 
proportional to the object’s stiffness (i.e., inversely 
proportional to the object’s elasticity). The law is 
mathematically expressed as E = 3φv2, where E 
represents Young’s modulus (expressed in kPa), φ 
represents the tissue density (expressed in kg/m3, 
assumed to be the same as water) and v shear 
represents the wave velocity (expressed in m/s). 
Young’s modulus clinically corresponds to the LSM 
and is typically referred to as E or LSM. The practical 
application is made possible using a probe that emits 
two types of waves. The probe (piston) initially causes 
a slow-spreading low-frequency (50 Hz) shear wave, 
after which the fast ultrasound waves (emitted from 
the same probe) in a pulse-echo fashion are used 
to determine the position of the shear wave front in 
relation to time; thus, the velocity of the shear wave 
and hence the LSM are determined. LSM values range 
from 1.5 to 75 kPa; lower values indicate a more 
elastic liver. The shear waves spread from the point 
of skin impact in a spherical manner, whereas the 
ultrasound waves are released in a straight line along 
the probe’s axis, i.e., in one dimension. To ensure that 
the measurements are accurate and reproducible in 
the same patient and are comparable among different 
patients, the accompanying software modifies the 
shear wave characteristics by maintaining the shear 
wave frequency and shape while modifying the shear 
wave amplitude and energy output. Thus, the full 
name of the method is vibration-controlled 1D TE. The 
results are also affected by the amount of pressure 
applied to the probe, in which a lack of pressure 
results in incomplete contact with the underlying 
skin, whereas too much pressure modifies the shear 
wave by changing the stiffness of the underlying 
tissue. These errors are prevented by the software, 
which displays warning signs and disables probe 
activation when the applied pressure is not adequate 
for measurement[36,37]. The applied technical solutions 
have resulted in high intra- and interobserver levels 
of agreement, 98% in both cases, according to 
clinical data[38]. The resulting LSM is translated into an 
estimate of the level of liver fibrosis in a simple and 
straightforward manner. However, this is estimation 
is possible only under the assumption that the liver 
is homogeneous and non-viscous, and its elasticity 
is predominantly affected by the level of fibrosis. 
This feature is true for liver parenchyma; however, a 
problem arises with regard to the capsule of Glisson. 
The capsule is a sturdy tissue that provides the liver 
with its form and protects it from mechanical injuries. 
It adapts over time to changes in the liver size; 
however, it does not respond well to abrupt changes. 
Consequently, a rapidly developing mass effect inside 
the liver will increase the intrahepatic pressure and 
thereby reduce the liver elasticity. These conditions 
include right-sided (global) congestive heart failure, 
acute inflammation and/or edema of the hepatic 
not discuss the use of the various NAFLD diagnostic 
techniques[3]. In everyday clinical practice, biomarkers 
are needed to determine excess fat in the liver, as well 
as inflammation and fibrosis of the liver. However, it 
is less likely that specific proteins/biomarkers will be 
identified for the detection of liver steatosis/fibrosis. 
Whether currently available biomarkers for NAFLD 
severity are useful in monitoring NAFLD progression 
(or regression) in people with MetS is uncertain. In 
recent years, substantial attention has been focused 
on one dimensional transient elastography (TE). 
TE is a non-invasive ultrasound-based method that 
uses shear wave velocity to assess tissue (e.g., liver) 
stiffness. Shear (secondary or S-) waves were initially 
discovered in seismology as slow waves that follow 
the primary compressional wave, hence their name. 
They are the manifestation of elastic waves that travel 
through the body of an object, as opposed to the 
surface waves, which, as the name implies, travel on 
the surface. In contrast to sound waves, which are 
longitudinal, shear waves are transverse, thus the 
motion of the affected tissue is perpendicular to the 
direction of wave propagation. As a result, shear waves 
move slowly (< 50 m/s) and are rapidly attenuated by 
liver parenchyma. This effect depends on the elastic 
properties of the tissue, with the speed of shear waves 
inversely proportional to the tissue elasticity. The 
method was designed at the Langevin institute in 1995 
and was initially implemented for quality control in the 
food industry; however, since 2001, it has been applied 
in medical practice under the name FibroScan®[33].
In practical terms, the TE device consists of a 
vertically oriented mobile cuboid main body and one or 
several cylindrical probes. Measurements are performed 
on patients lying supine with their right rib cage spread 
(which is accomplished by elevating the right hand 
and/or crossing the right leg over the left). After gel 
application, the probe is positioned perpendicular 
to the skin surface in one of the intercostal spaces 
adjacent to the right lobe of the liver (typically the 9th 
to 11th intercostal space, on the midaxillary line). Shear 
waves are affected by changes in the medium density, 
particularly in the presence of liquid medium; thus, the 
operator must avoid large vascular structures. To avoid 
this problem and ensure better results, the TE device is 
equipped with a small scale, real-time, ultrasonographic 
display of the tissue that underlies the probe in both 
A- and M-modes. After adequate positioning, a low 
frequency shear wave is induced by a small piston 
positioned on the tip of the probe that hits the skin 
surface. On the basis of the physical characteristics 
(velocity and intensity attenuation) of the shear wave, 
the acquired data are processed and displayed on the 
screen as the liver stiffness measurement (LSM) and 
controlled attenuation parameter (CAP). Unsuccessful 
measurements are automatically excluded by the 
device; the numerical results are not displayed, and the 
message “invalid measurement” is displayed[34,35].
The measurement of liver stiffness is based 
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tissue, and extrahepatic cholestasis[39-41]. Therefore, 
in everyday practice, LSM is not an absolute measure 
of liver fibrosis but is instead a component of liver 
assessment and cannot be interpreted independently 
of other clinical results (e.g., anamnesis, physical 
examination, laboratory tests, and imaging methods). 
Interestingly, food intake and alcohol consumption 
have also been demonstrated to affect LSM. Regarding 
food intake, different studies have reported varying 
results; however, a minimum two-hour fast is currently 
recommended prior to the exam[42,43]. Active alcohol 
consumption appears to lead to an overestimation of 
the LSM because one study has found that patients 
who were actively drinking at the first TE exam and 
subsequently stopped had significantly lower LSM 
values at the control TE exam several months later[44].
The basis for TE development was the measure-
ment of liver stiffness; thus, LSM has been present in 
TE devices from its inception. However, conventional 
ultrasonography has demonstrated that liver steatosis, 
another important liver parameter, affects ultrasound 
waves by strongly attenuating their intensity. The 
changes in signal attenuation are followed by an 
increased reflection of incoming ultrasound waves, 
which results in the liver appearing bright (hype-
rechoic). The main problems with conventional 
ultrasonography are its subjective operator-dependent 
nature and multiple uncontrolled variables included 
in the examination, which decrease the sensitivity of 
the examination in the detection of liver steatosis. 
The effect is more pronounced when small amounts 
of fat are observed, and the sensitivity becomes 
substantially lower (12% in patients with a 5%-9% fat 
content in contrast to 80% in patients with a ≥ 30% 
fat content)[45]. The theoretical background consists of 
the formula for intensity attenuation: Iz = I0e-αf∙z, where 
Iz represents the ultrasound intensity (expressed in 
W/m2) at depth z (expressed in m), I0 represents the 
initial intensity (expressed in W/m2) and αf represents 
the ultrasound attenuation coefficient (expressed in 
dB/m). The αf coefficient is primarily affected by two 
parameters, including the frequency of the emitted 
ultrasound wave and the properties of the conducing 
object (liver). With a fixed and known frequency (3.5 
MHz), αf is directly affected and proportional to the level 
of steatosis; thus, it is typically referred to as the CAP. 
CAP values range from 100 to 400 dB/m, and higher 
numbers indicate more pronounced steatosis. The 
advantage of CAP is that it is simultaneously calculated 
with the LSM and from the same region of interest. 
The clinical application of CAP began in 2011, ten years 
after the introduction of LSM[46].
The benefit of TE compared with liver biopsy is 
that it measures a larger region of interest, namely, 
a cylindrical liver segment 1 cm wide and 4 cm long 
at a medium depth of 4.5 cm. This region amounts 
to a volume of 3 cm3, which is approximately 100 
times larger than the volume of the liver cylinder 
obtained by liver biopsy. The drawback is that the 
information (LSM and CAP) cannot be obtained by a 
single measurement. The final result is obtained as a 
median of at least 10 measurements. The procedure 
is deemed a failure if 10 valid measurements cannot 
be obtained, the percentage of valid measurements 
compared with the total number of measurements 
is less than 60% and/or the interquartile range 
exceeds 30% of the median[47]. Boursier et al[48] have 
investigated a group of 1165 chronic liver disease 
patients and have determined that an interquartile 
median ratio ≤ 10% is the best predictor of accuracy. 
In addition to the previously described factors that 
are controlled by the device, two important factors 
that increase the measurement failure and may 
be only partially offset by the device include the 
body size and intercostal space width. Similarly to 
conventional ultrasonography, the body mass index 
(BMI) negatively affects TE measurements, resulting in 
falsely increased LSM values in obese individuals and 
rendering the standard probe unreliable in patients 
with a BMI ≥ 28 (30) kg/m2. A study by Castéra et 
al[49] has reported a 3.1% failure rate for obtaining 
valid results, which was associated with a BMI ≥ 30 
kg/m2 (OR = 7.5) and operator inexperience (defined 
as having performed fewer than 500 examinations, OR 
= 2.5). The number of unreliable results was higher 
and affected 15.8% of the examined patients; again, 
unreliability was related to a BMI ≥ 30 kg/m2 (OR = 
3.3) and operator inexperience (OR = 3.1). Of the 
obesity measures, LSM failure and LSM unreliability 
were predominantly related to waist circumference (> 
80 cm in women, > 94 cm in men; OR = 3.0). To solve 
this problem, a new probe was developed with a more 
sensitive ultrasound transducer using a lower shear 
wave frequency, increased vibration amplitude, deeper 
focal length (mean depth 5.5 cm) and a greater depth 
of measurement. The probes were renamed after 
clothing sizes, and the standard probe represents the 
M probe, whereas the new probe represents the XL 
probe. Similar problems regarding narrow intercostal 
spaces have been identified in children and asthenic 
adults, thus necessitating the development of the 
S probe. Similarly to the M probe, the new probes 
could initially measure only the LSM; however, this 
issue has been resolved with the adjustment of 
CAP measurements for the new probes[50-53]. The 
advantages and disadvantages of TE are summarized 
in Tables 1 and 2.
The main initial clinical focus of TE was to assess the 
level of liver fibrosis (LSM) in patients with chronic viral 
hepatitis and to reduce the need for invasive procedures 
(liver biopsy). To date, the studies performed have 
demonstrated a good correlation of LSM with liver biopsy 
in the identification of significant liver fibrosis (F ≥ 2) 
and cirrhosis (F4). The AUROC for the identification 
of significant fibrosis in hepatitis B patients (cut-off 
values from 5.2 to 8.0 kPa) ranges from 0.86 to 0.97, 
with a sensitivity range of 70%-94% and a specificity 
range of 38%-99%. The AUROC for the identification 
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of significant fibrosis in hepatitis C patients (cut-off 
values from 5.2 to 9.5 kPa) ranges from 0.73 to 0.91, 
with a sensitivity range of 56%-97% and a specificity 
range of 32%-91%. Regarding cirrhosis, the AUROC 
for identification in hepatitis B patients (cut-off values 
from 9.7 to 14.0 kPa) ranges from 0.80 to 0.97, with 
a sensitivity range of 52%-98% and a specificity 
range of 59%-99%. The AUROC for the identification 
of cirrhosis in hepatitis C patients (cut-off values from 
11.9 to 14.8 kPa) ranges from 0.87 to 0.98, with a 
sensitivity range of 72%-94% and a specificity range 
of 85%-98%[39,54-69]. In summary, TE is better at the 
identification of liver cirrhosis compared with significant 
fibrosis (mean AUROC 94% vs 84%, respectively), and 
among hepatitis patients, it is better at excluding than 
confirming liver cirrhosis (negative predictive value 
96%, positive predictive value 74%)[70,71]. The main 
drawback is the lack of clear-cut cut-off values for 
different stages of liver fibrosis because the ranges for 
different fibrosis levels often overlap, particularly with 
lower levels of liver fibrosis. One recently published 
meta-analysis including 4386 chronic hepatitis B 
patients has confirmed these statements. The meta-
analysis has indicated cut-off values for significant 
fibrosis (F ≥ 2), a fibrosis level ≥ 3 and cirrhosis 
in the following ranges: 5.85-8.8 kPa, 7.0-13.5 kPa 
and 9.0-16.9 kPa, respectively. The respective mean 
AUROCs for the cut-off values are 0.88, 0.91 and 0.93, 
respectively. Thus, the increasing accuracy of TE in the 
diagnosis of higher levels of fibrosis should be noted, 
as well as the substantial range in the cut-off values 
used in different studies. The latter finding may be 
explained by the differences in the cirrhosis prevalence 
in the studies, which affects the interpretation of 
the results, as well as the significance of the cut-off 
values[72].
Despite the shortcomings, the role of TE in the 
assessment of the level of fibrosis in viral hepatitis 
patients has been recognized by the most recent EASL 
guidelines[54,73,74]. TE is currently considered to be the 
non-invasive standard for the measurement of liver 
stiffness, and it is the most accurate non-invasive 
method for the identification of liver cirrhosis in patients 
with chronic viral hepatitis[55]. Consequently, initial 
hepatitis C (HCV) staging includes the performance 
of TE to exclude liver cirrhosis. The gold standard 
for the non-invasive assessment of the degree of 
fibrosis includes performing TE with serum biomarkers 
because of the superior accuracy in comparison with 
that of either test alone. However, the use of two 
tests also results in increased costs, as well as the 
need to perform a liver biopsy when the tests are 
not in agreement[59,75,76]. In the case of hepatitis B 
(HBV), values less than 5-6 kPa indicate absent or 
minimal liver fibrosis, whereas values greater than 
12-14 kPa are highly suggestive of cirrhosis. TE is also 
recommended in the initial assessment for HBV. 
The use of TE in HCV patients to monitor the therapeutic 
response (reversal of cirrhosis) is discouraged because 
of a lack of clinical data. Even more disappointing, 
a single study has demonstrated a low sensitivity of 
61% with 95% specificity in determining the reversal 
of cirrhosis[77]. Regarding HBV, the disease activity is a 
primary concern because inflammation and increased 
ALT levels are correlated with the overestimation of 
liver stiffness. The recommendations prompt the use 
of TE at least several months after ALT normalization 
to reduce the number of false positive results and to 
obtain a realistic value of the liver stiffness. However, 
the use of TE has been demonstrated to have a good 
prognostic value regarding the development of HCC. 
This association was initially identified in cross-sectional 
studies; however, because of the study design, the 
prognostic value could not be established[78,79]. Proof has 
come from subsequent prospective longitudinal studies 
that have demonstrated a progressive increase in the 
risk of HCC development with increased initial LSM 
values (Table 3)[80,81].
7241 August 28, 2016|Volume 22|Issue 32|WJG|www.wjgnet.com
Table 1  Limitations of transient elastography with controlled 
attenuation parameter
Limitations Explanation
Ascites Elastic waves do not travel through liquids
Obesity BMI > 30 kg/m2 is associated with TE failure. With 
the development of the XL probe, the failure rate in 
obese patients has decreased
Acute hepatitis Tissue changes in acute hepatitis may increase LSM
Chronic 
hepatitis with 
transaminases 
flare
At ALT levels greater than 5 × the upper normal 
limit, there is a risk of overestimating the fibrosis 
stage. LSM interpretations in patients with high 
ALT levels must be made with caution
Extrahepatic 
cholestasis
Increases LSM independently of fibrosis stage
Congestive heart 
failure
May lead to increased LSM because of an increased 
blood volume in the liver
Narrow intercostal 
spaces
Associated with a lower success rate or failed 
acquisition of LSM. Reduced failure rate with the 
development of the S probe
BMI: Body mass index; LSM: Liver stiffness measurement; ALT: Alanine-
aminotransferase.
Table 2  Advantages of transient elastography with controlled 
attenuation parameter
Most widely used and validated non-invasive technique
High range of values
Well defined quality criteria
Good reproducibility
Detects liver stiffness and steatosis from the same region of interest
Excellent for the exclusion of cirrhosis
Prognostic value in cirrhosis
User-friendly
Short duration, painless
Applicable as a screening method in large populations
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LSMS FOR THE PREDICTION OF 
FIBROSIS STAGE IN NAFLD 
In daily clinical practice, specific biomarkers are 
needed that will demonstrate the amount of excess 
fat present in the liver, the level of fibrosis and the 
level of inflammation. In patients with NAFLD, the 
most important factor is the assessment of fibrosis 
severity and monitoring fibrosis progression. Most 
patients remain asymptomatic until their liver function 
is compromised; thus, the identification of the pre-
sence and severity of liver fibrosis remains a clinical 
challenge. This issue is important because efficient 
treatment for NAFLD has not yet been established. 
Therefore, the identification of risk factors for HCC and 
liver cirrhosis, such as liver fibrosis, should facilitate the 
implementation of risk-reduction mechanisms in NAFLD 
patients[82,83]. For the evaluation of fibrosis severity, a 
liver biopsy represents the “gold standard” in various 
liver diseases. Nevertheless, it is restricted by its 
complications and costs[84]. It is unrealistic to perform 
a liver biopsy for the diagnosis or monitoring of disease 
progression on all patients because 15%-40% of adults 
have NAFLD. 
Despite the potential presence of high risk factors 
for fibrosis in NAFLD patients, such as diabetes, the 
population remains too large to implement an invasive 
method to exclude fibrosis[84,85]. Thus, noninvasive 
methods have been intensively investigated[84]. The 
various approaches include standard biochemical 
and hematological tests, surrogate fibrosis markers 
in the blood and their algorithms and, the most 
recently investigated approach, TE[85]. To date, TE 
assessment of liver fibrosis has predominantly been 
implemented in patients with chronic viral hepatitis, 
as well as patients with other chronic liver diseases of 
different etiologies[86]. Recent studies have examined 
the usefulness of LSM compared with liver biopsy 
to identify fibrosis in NAFLD patients. Table 4 shows 
details of eight studies that have examined the 
usefulness of LSMs in the identification of different 
stages of liver fibrosis in NAFLD patients compared 
with liver biopsy[83,84,87-92]. In these studies, for F ≥ 2, 
the LSM cut-off values range from 6.2 to 11 kPa, with 
62%-90% sensitivity and 74%-100% specificity. For 
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Table 3  Hazard ratio of hepatocellular carcinoma development 
in relation to liver stiffness measurement (according to 
Masuzaki et al [80] and Jung et al [81])
HCV HBV
LSM (kPa) HR LSM (kPa) HR
10.1-15 16.7 13.1-18 4.68
15.1-20 20.9 18.1-23 5.55
20.1-25 25.6 > 23 6.60
> 25 45.5
HCV: Hepatitis C virus infection; HBV: Hepatitis B virus infection; LSM: 
Liver stiffness measurement.
F ≥ 3, the LSM cut-off values range from 8 to 12 kPa, 
with 84%-100% sensitivity and 83%-97% specificity. 
For F4, the LSM cut-off values range from 9.5 to 20 
kPa, with 90%-100% sensitivity and 75.9%-98.4% 
specificity.
A meta-analysis[93] in 2014 has indicated that TE is 
excellent in diagnosing F ≥ 3 (85% sensitivity, 82% 
specificity) and F4 (92% sensitivity, 92% specificity), 
and it has a moderate accuracy for F ≥ 2 in NAFLD 
Study Probe Cut-off 
(kPa)
Sensitivity Specificity Number 
of patients 
with liver 
biopsy
Fibrosis stage ≥ F2
Imajo et al[83] 
(2016)
M 11.0      61.7 100 142
Pathik et al[84] 
(2015)
M   9.1 Not 
reported
Not 
reported
110
Yoneda et al[87] 
(2007) 
M     6.65      81.8 91.2   67
Cassinotto et al[88] 
(2015)
M   6.2 ≥ 90 Not 
available
291
Wong et al[89] 
(2010) 
M   7.0   88 74 246
Lupsor et al[90] 
(2010)
M   6.8   67 84   72
Yoneda et al[91] 
(2008)
M     6.65   88 74   97
Kumar et al[92] 
(2013) 
M   7.0   78 79 205
Fibrosis stage ≥ F3
Imajo et al[83] 
(2016) 
M 11.4      85.7    83.8 142
Pathik et al[84] 
(2015) 
M 12.0   90 80 110
Yoneda et al[87] 
(2007) 
M   8.0      87.5    84.3   67
Cassinotto et al[88] 
(2015) 
M   8.2 ≥ 90 Not 
available
291
Wong et al[89] 
(2010) 
M   8.7   84 83 246
Lupsor et al[90] 
(2010) 
M 10.4 100 97 72
Yoneda et al[91] 
(2008) 
M   9.8   85 81     97
Kumar et al[92] 
(2013)
M   9.0   85 88 205
Fibrosis stage F4
Imajo et al[83] 
(2016) 
M 14.0 100    75.9 142
Pathik et al[84] 
(2015) 
M 20.0   90 80 110
Yoneda et al[87] 
(2007)
M 17.0 100    98.4   67
Cassinotto et al[88] 
(2015) 
M 9.5  ≥ 90 Not 
available
291
Wong et al[89] 
(2010) 
M 10.3   92 97 246
Yoneda et al[91] 
(2008) 
M 17.5 100 97   97
Kumar et al[92] 
(2013)
M 11.8   90 88 205
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Table 4  Usefulness of liver stiffness measurement compared 
with liver biopsy in the detection of fibrosis in nonalcoholic 
fatty liver disease patients
patients. LSMs were performed with an M probe, and 
obesity was the major reason for unsuccessful LSM. 
This problem may be avoided with the use of the novel 
XL probe. In a study by Wong et al[94], the XL probe 
was used to identify fibrosis in 193 NAFLD patients 
with a BMI ≥ 30 kg/m2 compared with liver biopsy, “the 
gold standard”. Ten valid measurements were obtained 
in 93% of the patients, with AUROCs of 0.80, 0.85 and 
0.91 for F ≥ 2, F ≥ 3 and F4, respectively. In a study 
conducted by Friedrich-Rust et al[85], the AUROC for 
significant fibrosis diagnosis (F ≥ 2) for the XL probe 
was 0.82 compared with 0.84 for a severe fibrosis 
diagnosis (F ≥ 3) and 0.95 for an F4 diagnosis. This 
study demonstrates that when measured with the 
XL probe, the median LSM is significantly lower than 
that measured with the M probe (6.9 kPa vs 8.4 kPa, 
respectively). According to these two studies, the 
LSM cut-off values should be approximately 1.5-2 kPa 
lower when the XL probe is used rather than the M 
probe for the same stage of fibrosis. This issue justifies 
the need for more studies on this topic because the 
existing cut-off values, which are defined for the M 
probe, cannot be used for the XL probe. Available data 
indicate that in patients with NAFLD, TE is a highly 
accurate, non-invasive method for advanced fibrosis 
exclusion and a moderately accurate method for 
significant fibrosis exclusion.
The use of paired biopsies for monitoring the 
progression of the disease in NAFLD patients has been 
reported. A prospective four-year study has been 
conducted by Suzuki et al[95], in which the disease 
progression in NAFLD patients was evaluated using TE. 
Ninety-seven NAFLD patients (demonstrated by liver 
biopsy) had their LSM obtained at the beginning of the 
study; of the 97 patients, 36 patients were available 
for reevaluation after four years, in which their stage 
of fibrosis was compared with that from their initial 
assessment. The authors concluded that LSM may be 
used to monitor hepatic fibrosis severity in patients 
with NAFLD. Nevertheless, additional prospective 
studies regarding the monitoring of LSM progression in 
patients with NAFLD are necessary.
CAP FOR THE PREDICTION OF 
STEATOSIS GRADES IN NAFLD
Liver steatosis may be defined radiologically as a fat 
mass comprising ≥ 5% of the wet weight of the liver 
or histologically as a fatty deposit presence in ≥ 5% 
of hepatocytes. Metabolic dysfunction of the liver 
may develop over time as a result of liver steatosis, 
which may consequently progress into irreversible 
damage to the liver, with the development of fibrosis, 
cirrhosis and HCC[96]. Steatosis of the liver is a key 
parameter in liver transplantation. Because any liver 
with a fat content > 30% is automatically ineligible 
for donation, determining the liver steatosis level is of 
substantial importance for the evaluation and clinical 
prognosis of patients with NAFLD[83]. Efforts regarding 
the development of reliable non-invasive methods for 
liver steatosis detection and quantification have been 
made over the past 10 years[96,97]. A strong correlation 
of CAP with fat accumulation in the liver (demonstrated 
by liver biopsy) has been identified in clinical studies 
investigating TE with CAP; moreover, CAP has been 
reported to be useful in the diagnosis of steatosis of 
the liver in numerous chronic liver diseases[83,96-104]. 
Table 5 shows that (similarly to the LSM cut-off values) 
the different CAP cut-off values presented by different 
studies for distinct grades of liver steatosis defined by 
biopsy (range from S0, which indicates no steatosis, 
to S3, which indicates the highest level of steatosis); 
for S ≥ 1 (≥ 10% of hepatocytes with fat), the CAP 
cut-off values range from 214 to 289 dB/m, with a 
64%-91% sensitivity range and a 64%-94% specificity 
range; for S ≥ 2 (≥ 33% hepatocytes with fat), the 
CAP cut-off values range from 255 to 311 dB/m, 
with a 57%-96% sensitivity range and a 62%-94% 
specificity range; finally, for S3 (≥ 66% hepatocytes 
with fat), the CAP cut-off values range from 281 to 
310 dB/m, with a 64%-100% sensitivity range and 
a 53%-92% specificity range. According to these 
studies, CAP is useful in the detection of S ≥ 1, S ≥ 2, 
and S3 steatosis as a result of its good sensitivity and 
specificity; however, the exact cut-off values remain to 
be defined[83,98-103,105].
De Lédinghen et al[104] conducted a study in 2014 
regarding the diagnosis of S1, S2 and S3. The cumulative 
AUROCs of CAP were 0.79 (95%CI: 0.75-0.84), 0.84 
(95%CI: 0.80-0.88) and 0.84 (95%CI: 0.80-0.88), 
respectively. The study included 440 patients who had 
undergone a liver biopsy. Compellingly, obesity (defined 
as a BMI >30 kg/m2) was determined to be the main 
cause of CAP measurement failure. It must be taken 
into account that both the 2014 de Lédinghen study 
and all studies described in Table 5 excluded the 
benefits of the CAP-enabled XL probe by using only 
the M probe. Furthermore, these studies demonstrate 
that the CAP cut-off values are not affected by the 
cause of the chronic liver disease, in contrast to LSM, 
in which the cut-off values depend on the type of liver 
disease[101].
WHAT IS THE POSITION OF TE WITH 
CAP IN THE ASSESSMENT OF NAFLD?
The significance of metabolic factors in the patho-
genesis of NAFLD has been emphasized by numerous 
studies. As previously discussed, at least one 
component of MetS is present in approximately 90% of 
patients with NAFLD, whereas all diagnostic criteria for 
MetS are met in 35%-75% of patients. Furthermore, 
the risk for NAFLD is increased 4-11 times by the 
presence of MetS[3,106-109]. Mena et al[110] have identified 
an association between different MetS components 
and fibrosis in chronic hepatitis B patients. The pre-
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sence of multiple MetS components is associated with 
fibrosis development, whereas significant fibrosis is 
uncommon in the absence of MetS. 
The occurrence of NAFLD has increased as a result 
of the rapid increase in the prevalence of metabolic risk 
factors. Patients with NAFLD are at risk for liver-related 
morbidity and mortality. Numerous recent studies have 
indicated a significantly increased incidence of HCC in 
obese patients and patients with T2DM, and moreover, 
increasing evidence suggests an increased risk of 
HCC in NAFLD patients. As a result of the increasing 
incidence of NAFLD, an increase in NAFLD-related HCC 
is expected in the future[111].
The risk of developing CVD, CKD and T2DM in long-
term follow-up is increased by the presence of NAFLD. 
The course of these diseases is also affected by NAFLD, 
because it increases the CVD and CKD risk. Moreover, 
NAFLD and MetS are more tightly associated because 
the presence of one condition increases the risk of 
developing the other condition. From a therapeutic 
standpoint, the prevention and treatment of hepatic 
IR, MetS and related complications represent a rational 
approach in reversing NAFLD, which is why various 
specialists, such as hepatologists, nephrologists, 
endocrinologists, cardiologists, general internists, and 
primary care physicians, should be involved in the care 
of NAFLD patients[108,112]. The strongest predictor of the 
progression of liver disease in NAFLD patients is the 
presence of NASH at the initial liver biopsy. In addition, 
the main determinant of all-cause and cause-specific 
mortality in patients with NAFLD is the severity of liver 
fibrosis[105-107,113,114]. Complicating matters, a recent 
study conducted by McPherson et al[114] has reported 
that 44% of the patients with simple steatosis at the 
index liver biopsy progressed to NASH, whereas in 
37% of the patients, fibrosis progression was present 
at the follow-up biopsy. Furthermore, at the follow-
up biopsy, 22% of the patients with baseline simple 
steatosis reached stage three fibrosis. The progression 
potential from simple steatosis to fibrosis and NASH 
has also been confirmed by other small studies[115,116]. 
An association between non-cirrhotic NAFLD and HCC 
risk has been demonstrated in recent studies[117,118]. 
According to a study in the United States, conducted 
between 2002 and 2008, the most common underlying 
risk factor for HCC is NAFLD, followed by T2DM and HCV 
infection[119]. Thus, contrary to current opinion, simple 
steatosis may progress to NASH and significant fibrosis, 
which, in turn, would indicate that most patients 
with NAFLD are at long-term risk of progressive liver 
disease[114-116]. Liver biopsy is the gold standard for 
liver fibrosis assessment; however, its limitations, 
complications and cost, given that approximately 
one-third of the population has NAFLD, make it unrea-
sonable to perform it on all patients. A substantial 
number of physicians consider liver biopsy to be a 
diagnostic tool in patients who persistently exhibit 
increased liver function tests because of the substantial 
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Table 5  Performance of controlled attenuation parameter compared with liver biopsy for the detection of various steatosis grades
Study Etiology of CLD Probe Cut-off 
(dB/m)
AUC Sensitivity 
(%)
Specificity 
(%)
Number of patients 
with liver biopsy
Steatosis grade ≥ 1
Sasso et al[98] (2010) CLD, ALD, NAFLD M 238 0.91 91 81 115
de Lédinghen et al[100] (2012) NAFLD, HCV, ALD, other M 266 0.84 69 85 112
Shen et al[102] (2014) NAFLD, HBV M 253 0.92 88 83 189
Kumar et al[101] (2015) HBV, HCV, NAFLD M 214 0.68 64 64 317
Myers et al[99] (2012) Hepatitis, NAFLD, other M 289 0.79 68 88 153
Chan et al[103] (2014) NAFLD, control M 263 0.97 91 94 101
Imajo et al[83] (2016) NAFLD, control M 236 0.88 82.3 91 127
Lupșor-Platon et al[105] HCV, HBV, NAFLD, other CLD M 260 0.81 64.8 82.3 201
Steatosis grade ≥ 2
Sasso et al[98] (2010) CLD, ALD, NAFLD M 259 0.95 89 86 115
de Lédinghen et al[100] (2012) NAFLD, HCV, ALD, other M 311 0.86 57 94 112
Shen et al[102] (2014) NAFLD, HBV M 285 0.92 93 83 189
Kumar et al[101] (2015) HBV, HCV, NAFLD M 255 0.79 77 80 317
Myers et al[99] (2012) Hepatitis, NAFLD, other M 288 0.76 85 62 153
Chan et al[103] (2014) NAFLD, control M 263 0.86 96 67 101
Imajo et al[83] (2016) NAFLD, control M 270 0.73 64.3 73.6 127
Lupșor-Platon et al[105] HCV, HBV, NAFLD, other CLD M 285 0.82 69.7 85.1 201
Steatosis grade 3
Sasso et al[98] (2010) CLD, ALD, NAFLD M 292 0.89 100 78 115
de Lédinghen et al[100] (2012) NAFLD, HCV, ALD, other M 318 0.93   87 91 112
Shen et al[102] (2014) NAFLD, HBV M 310 0.88   92 79 189
Kumar et al[101] (2015) HBV, HCV, NAFLD M 305 0.91   71 92 317
Myers et al[99] (2012) Hepatitis, NAFLD, other M 283 0.70   94 47 153
Chan et al[103] (2014) NAFLD, control M 281 0.75 100 53 101
Imajo et al[83] (2016) NAFLD, control M 302 0.70 64.3 73.6 127
Lupșor-Platon et al[105] (2015) HCV, HBV, NAFLD, other CLD M 294 0.83 83.3 82.5 201
CLD: Chronic liver disease; ALD: Alcoholic liver disease; NAFLD: Nonalcoholic fatty liver disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus.
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number of patients at risk (T2DM, obesity, arterial 
hypertension, dyslipidemia and/or MetS). However, it 
must be considered that in more than half of NAFLD 
patients, aminotransferases are within the normal 
limits; therefore, deciding which patients with NAFLD 
are candidates for liver biopsy and how to monitor their 
liver disease progression leaves gastroenterologists 
with more questions than answers[120].
According to the most recent guidelines by the 
American Association for the Study of Liver Diseases 
(AASLD) in 2012[121], liver biopsy should be considered 
in high-risk patients with NAFLD, patients with an 
increased risk of NASH and advanced fibrosis. The 
presence of T2DM, MetS and/or an age > 50 years are 
risk factors. Systematic screening, at least for higher-
risk patients (diabetic and obese patients), has been 
argued for by many authors. According to the AASLD 
guidelines, “screening for NAFLD in adults attending 
primary care clinics or high-risk groups attending 
diabetes or obesity clinics is not advised at this time 
because of the uncertainties surrounding diagnostic 
tests and the cost-effectiveness of screening”[121]. That 
guidelines were published in 2012 must be considered, 
and given the new data accumulating, updated guide-
lines are urgently needed.
MetS may be used to identify patients as candidates 
for liver biopsy, specifically when it is present with a 
noninvasive marker of liver steatosis/fibrosis because 
it predicts the presence of steatohepatitis in patients 
with NAFLD. TE with CAP may find its place in this 
approach, according to recent investigations. Intere-
stingly, a study conducted by de Lédinghen et al[104] 
has demonstrated that the CAP value significantly 
increases with the number of parameters of MetS, BMI, 
waist circumference, presence of arterial hypertension 
and T2DM. Our recent analysis, including 648 patients 
with one or more components of MetS, has provided 
similar results; specifically, the CAP measurements 
progressively increase with the number of MetS 
components. In addition, the presence of MetS (or 
its individual components), IR, increased uric acid 
levels and an LSM > 7 kPa are factors independently 
associated with increased CAP (unpublished data). 
Kwok et al[113] have analyzed 1900 patients with T2DM 
for NAFLD using TE with CAP and have determined 
prevalence rates of increased CAP and LSM of 72.8% 
and 17.7%, respectively. Furthermore, that study 
included 94 T2DM patients with suspected advanced 
fibrosis or cirrhosis who had undergone liver biopsy, 
and of these 94 patients, 56% had NASH, 21% had 
advanced fibrosis and 29% had cirrhosis. Naveau et 
al[122] have analyzed 100 patients who were candidates 
for bariatric surgery. TE was performed 15 d prior to 
liver biopsy. The AUROC generated by TE was 0.81 
± 0.05 for the prediction of fibrosis stage F ≥ 2 and 
0.85 ± 0.04 for the prediction of fibrosis stage F3. The 
authors have concluded that TE may be used for the 
early diagnosis of fibrosis in severely obese patients. 
In a similar study of hospitalized diabetic patients, de 
Ledinghen et al[123] have demonstrated an increased 
prevalence of severe fibrosis (defined by LSM), which 
was the highest in the > 50 year-old group of T2DM 
patients. Cho et al[2] have tested the feasibility of TE 
with CAP in 201 children in a comparison of CAP and 
LSM values in obese children, non-obese healthy 
controls and non-obese patients with liver disease. The 
authors found that the CAP values were increased in 
the obese group compared with the other two groups. 
Furthermore, they identified significantly higher LSM 
values in the obese group compared with the healthy 
control; however, no statistically significant differences 
in the LSM values were identified between the group 
with liver disease and the other two groups. In the 
obese group, the LSM values were highly correlated with 
the CAP values, whereas there was no correlation in the 
healthy control group or the group with liver disease[2].
On the basis of the findings in the previously described 
studies, CAP and LSM have a good correlation with the 
presence of MetS and its individual components.
The potential effect of NASH on the course and 
prognosis of NAFLD is a significant issue. The gold 
standard for the diagnosis and follow-up of NASH 
is liver biopsy. According to the study by Friedrich-
Rust et al[85], the AUROC of TE for steatohepatitis 
diagnosis (according to the NAFLD activity score) was 
0.79 for the M probe and 0.74 for the XL probe. In 
the study by Cho et al[2], LSM was mildly increased in 
patients with steatohepatitis, which may be attributed 
to inflammation, whereas similar results have been 
obtained in patients with alcoholic liver disease[124]. 
Thus, there is a possibility that LSM values in obese 
patients may be affected by steatohepatitis[2]. The 
obtained results indicate the urgency to conduct 
additional research to further clarify the position of TE 
with CAP in steatohepatitis management. 
A subgroup of NAFLD patients (in the population 
of patients with one or more MetS components) who 
are at high risk of developing progressive liver disease 
may be identified by using TE with CAP because CAP 
and LSM show good correlations among MetS and 
its individual components and liver biopsy findings. 
The presence of MetS, which predicts the presence of 
steatohepatitis in NAFLD patients, in combination with 
a non-invasive method for liver fibrosis and steatosis 
detection may be used to identify candidate patients 
for liver biopsy. The identification of patients who are 
at risk for the development of NASH and advanced 
fibrosis and who require a liver biopsy may be 
performed through using MetS with high CAP values 
and particularly with increased LSM values. Available 
data suggest that to exclude advanced fibrosis in 
patients with NAFLD, TE is a highly accurate, non-
invasive method, whereas it is a moderately accurate 
method for excluding significant fibrosis in patients 
with NAFLD, which is why TE with CAP may eventually 
replace liver ultrasound in the initial evaluation of 
patients with NAFLD. Taking into account the early 
observations that MetS and its individual components 
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(T2DM and obesity) are risk factors for the progression 
of liver disease in NAFLD patients, the identification of 
patients in need of a liver biopsy may be accomplished 
when MetS and its components are present together 
with increased CAP and particularly increased LSM. 
As a result of the parallel increasing incidence of 
both NAFLD and obesity, T2DM and MetS, including 
the consequences of MetS and NAFLD, i.e., the asso-
ciated morbidity and mortality, the consideration of 
screening for NAFLD in all patients with one or more 
MetS components by a non-invasive method, such 
as TE with CAP, appears reasonable[125,126]. Per our 
analysis, increased CAP values have been found in 
patients with only one MetS component[126]. There is a 
disproportionately small number of studies conducted 
that have investigated TE in the setting of NAFLD and 
MetS, given that NAFLD is a common disease, and 
TE is becoming an increasingly used non-invasive 
method. Moreover, NAFLD is the most common cause 
of increased liver enzymes; however, it is critical to 
consider that AST and ALT may be within their normal 
ranges even in advanced NAFLD. Thus, the earlier 
opinion that NAFLD patients with persistently increased 
liver enzymes should be the only patients who undergo 
liver biopsy should be revised[125,126].
In parallel to the increasing need for a noninvasive 
assessment of liver fibrosis and steatosis, several 
imaging methods have emerged. Two other methods, 
in addition to TE, have shown promising results. The 
first method, acoustic radiation force impulse imaging 
(ARFI), is based on shear wave propagation, similarly 
to TE. Compared with TE, the inspected liver volume 
is smaller (1 cm in length); however, ARFI can be 
used on modified commercial ultrasound machines. 
Thus, the point of interest can be pinpointed using an 
ultrasound’s B-mode. The downside of this method 
includes a narrow range of results (0.5-4.4 m/s) 
with unclear cut-off values for different fibrosis stage 
levels. Bota et al[127] have summarized the studies 
comparing the two methods in a meta-analysis, 
indicating comparable sensitivity (0.87 with 95%CI: 
0.79-0.92 for ARFI vs 0.89 with 95%CI: 0.80-0.94 
for TE) and specificity values (0.87 with 95%CI: 
0.81-0.91 for ARFI vs 0.87 with 95%CI: 0.82-0.91 for 
TE) of both methods in the detection of liver cirrhosis. 
The reliability of the measurements is the principal 
difference between the two methods. ARFI fares better, 
with 2.1% unreliable results, compared with 6.6% 
for TE. The main reason for the unreliable results is 
obesity, and the studies included in the meta-analysis 
were based on TE measurements performed by the M 
probe; thus, these percentages should be interpreted 
with caution. The unreliability highlighted in that study 
is why the actual reliability difference between TE and 
ARFI must be re-assessed, including studies using the 
XL probe. Compared with TE, the inability to determine 
the level of steatosis is the clear disadvantage of AFRI. 
The other significant field of noninvasive liver fibrosis 
and steatosis assessment involves magnetic resonance 
imaging (MRI)-based methods. These approaches 
assess the liver in its entirety. The main advantage of 
MRI methods is that they are not affected by obesity 
or the presence of ascites. However, distinct methods 
are required to properly and independently assess liver 
fibrosis (e.g., MRI elastography) and steatosis (e.g., 
proton density fat fraction MRI). The high performance 
of MRI-based methods in assessment of advanced 
fibrosis (AUROC 0.957 with 95%CI: 0.918-0.996 
for 2D-MRI elastography), as well as steatosis levels 
(correlation coefficient for the quantification of liver 
steatosis of 0.82 for proton density fat fraction MRI) 
in NAFLD patients has been demonstrated in recent 
studies[128,129]. Although MRI-based methods have 
demonstrated better diagnostic performances in 
non-invasive liver fibrosis and steatosis detection in 
patients with NAFLD compared with TE with CAP, there 
are major factors that limit this method, particularly 
in monitoring of the progression of the disease; 
these factors include cost, patient claustrophobia and 
duration of the examination[83,125]. 
Several questions should be addressed with addi-
tional studies. First, the question arises as to whether 
TE with CAP may be used to monitor NAFLD progression 
and whether the progression of LSM values may be 
used as a parameter of liver fibrosis severity. Because 
the only treatment option for NAFLD includes lifestyle 
changes and individual MetS component treatment, the 
question arises as to whether monitoring the changes 
in the CAP and LSM values could be used to assess the 
treatment of individual MetS components and the effect 
of treatment on NAFLD. 
Second, taking into account portal hypertension, 
TE may potentially be useful in the identification of 
patients who are at risk of developing varices, as 
several studies have demonstrated. Furthermore, some 
studies have highlighted the potential utility of spleen 
stiffness measurements in the prediction of esophageal 
varices and portal hypertension level assessment in 
liver cirrhosis[124]. Thus, additional studies are required 
regarding this topic in patients with NAFLD.
The use of TE has been demonstrated to have a 
good prognostic value regarding the development of 
HCC in patients who suffer from viral hepatitis[78,79]; 
however, interestingly, there are no studies regarding 
the prediction of HCC development in patients with 
NAFLD via an assessment of the value of high LSM 
measurements. Thus, additional prospective studies 
are urgently required to answer this question. If 
the predictive value of TE with CAP were verified, 
clinicians would be able to assess and monitor the 
risk of HCC development and to establish optimal and 
personalized monitoring and treatment strategies in 
patients with NAFLD. Additional studies should also 
focus on investigating the accuracy of TE with CAP for 
all clinically significant events (i.e., liver cirrhosis and 
HCC) in patients with one or more MetS components.
Third, what is the place of TE with CAP in steato-
hepatitis detection? Yoneda et al[87] have demonstrated 
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a substantial increase of LSM in NASH patients, as 
confirmed by liver biopsy results; however, additional 
studies must be conducted. According to Yoneda et 
al[87], the LSM values are not affected by the degree of 
steatosis; however, additional studies must clarify this 
issue, and the influence of high grade steatosis on LSM 
values remains controversial.
Fourth, an investigation regarding whether the 
increased CAP and LSM values could predict the 
development of MetS in patients with one or two MetS 
components is needed. In addition, a question arises 
as to whether it is possible to monitor the changes in 
MetS and its individual components by monitoring the 
changes in CAP and LSM. 
Given the associations between NAFLD and CVD 
and CKD risks, additional studies should determine 
whether patients with NAFLD with both increased CAP 
and particularly an increased LSM might benefit from 
early CKD and CVD screening. Finally, large studies 
are required for the development of new cut-off values 
for liver fibrosis staging using the XL probe and to 
investigate the differences between the CAP cut-off 
values used for the M and XL probes, respectively[84].
In conclusion, an easy, quick and non-invasive mass 
screening for NAFLD in patients with one or more MetS 
components may be reasonably achieved with TE with 
CAP. Once NAFLD is diagnosed, particularly liver fibrosis 
using LSM values, these patients should be directed to 
hepatologists, diabetologists and nephrologists. If TE 
with CAP is used as a screening method, liver biopsy 
may consequently be avoided in a substantial number 
of patients. This approach may also be useful in the 
early diagnosis of associated metabolic abnormalities 
and may enable the appropriate treatment of MetS, 
which is highlighted by its being the only available 
treatment option for patients with NAFLD to date. The 
accuracy of TE with CAP in the prediction of clinical 
events (i.e., liver cirrhosis and HCC) in patients with 
one or more MetS components should be investigated 
in additional studies.
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